Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration [Yahoo! Finance]
KIRIN HLDGS CO LTD S/ADR (KNBWY)
US:NASDAQ Investor Relations:
kirinholdings.co.jp/english/ir
Company Research
Source: Yahoo! Finance
Amgen (AMGN) has just walked away from its licensing and collaboration agreement with Kyowa Kirin on rocatinlimab for atopic dermatitis, a portfolio reshuffle that shifts responsibility back to Kyowa Kirin and repositions Amgen's near term pipeline focus. See our latest analysis for Amgen. Those portfolio moves sit alongside a share price that has climbed to US$344.68, with a 30 day share price return of 5.2% and a 1 year total shareholder return of 23.14%, which suggests that momentum has been building rather than fading. If Amgen's repositioning has you thinking about other opportunities in this space, it could be a good moment to scan healthcare stocks for more ideas across the sector. With shares at US$344.68, an intrinsic discount of around 45% and a value score of 4, the key question is whether Amgen still offers mispriced upside or if the market is already factoring in future growth. Against a fair value estimate of about $327.74, Amgen's last close at $344.68 sits a
Show less
Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNBWY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNBWY alerts
High impacting KIRIN HLDGS CO LTD S/ADR news events
Weekly update
A roundup of the hottest topics
KNBWY
News
- Amgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook [Yahoo! Finance]Yahoo! Finance
- Kyowa Kirin to regain control of rocatinlimab development, commercialization [Yahoo! Finance]Yahoo! Finance
- Is Kyowa Kirin (TSE:4151) Pricing Look Attractive After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Amgen ends collaboration agreement with Kyowa Kirin for eczema asset [Seeking Alpha]Seeking Alpha
- Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic DermatitisGlobeNewswire